MLN Product (Revised): Intravenous Immune Globulin Items & Services
This revised Product comprises Subregulatory Guidance for Intravenous Immune Globulin (IVIG), and its content is based on publically available content within at Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012. CMS policy or operation subject matter experts also reviewed/cleared this product. This product educates on coverage, supplier eligibility, billing and coding requirements and claim edits. Revisions to this Product include following content updates:
• Refined claims processing instructions for the intravenous immune globulin (IVIG) permanent benefit (pages 1–4)
• Added IVIG coverage information (page 1)
• Added CY 2025 payment rate for Q2052 (page 2)
• Added a time increment table for reporting Q2052 (page 3)
• Added a new IVIG J-code for CY 2025 (page 4)
• Added place of service code 04 for claims processing (page 4)
The previous version of this product is available to the public and currently posted on the CMS website at https://www.cms.gov/files/document/intravenous-immune-globulin-demonstration.pdf.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: December 23, 2024
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.